• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary

    12/6/22 8:00:00 AM ET
    $ARAY
    $EDAP
    $HPQ
    $INTC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ARAY alert in real time by email

    LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value.

    Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rhodes's leadership team and will be key to supporting the ongoing expansion of our U.S. organization and driving the continued strong growth of our business in the U.S."

    Ryan Rhodes, Chief Executive Officer of EDAP Technomed Inc., stated, "Ken is the ideal candidate to be our subsidiary's first CFO as we begin to significantly ramp up the business with the growth of our flagship Focal One® Robotic HIFU platform. He brings over 25 years of financial leadership across all finance disciplines with extensive experience building strong relationships to drive operating results. His knowledge of capital equipment along with his medical device and investor relations experience at leading organizations, including Accuray, will be invaluable as we move forward."

    "EDAP Technomed Inc. is at a critical juncture in the organization's growth. I'm looking forward to working with Ryan and the extended team to accelerate growth in our U.S. business and provide more patients with access to our precise, innovative Focal One robotic technology," said Mr. Mobeck.

    Prior to joining EDAP Technomed, Ken served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Incorporated (NASDAQ:ARAY), one of the leading radiation therapy companies in the industry. During his tenure with the organization, he was responsible for driving key initiatives to improve the company's operating performance. Prior to joining Accuray, Ken served as Vice President of Finance at optical networking leader Lumentum (NASDAQ:LITE) where he helped raise $900 million in debt financing to grow the business from $900 million to more than $1.6 billion in only three years. Before Lumentum, he spent over two decades in positions with increasing levels of responsibility at some of Silicon Valley's most innovative companies including Silicon Graphics, Hewlett Packard (NYSE:HPQ), KLA (NASDAQ:KLAC) and Intel Corporation (NASDAQ:INTC), where he was involved in high scale growth, business transformation and mergers and acquisitions. Notably, while employed at KLA, he helped grow revenue from $1.3 billion to $2.7 billion over seven years.

    About EDAP TMS SA

    A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.

    Forward-Looking Statements

    In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

    Company Contact

    Blandine Confort

    Investor Relations / Legal Affairs

    EDAP TMS SA

    +33 4 72 15 31 50

    [email protected]

    Investor Contact

    John Fraunces

    LifeSci Advisors, LLC

    212-915-2568

    [email protected]

     



    Primary Logo

    Get the next $ARAY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY
    $EDAP
    $HPQ
    $INTC

    CompanyDatePrice TargetRatingAnalyst
    Lumentum Holdings Inc.
    $LITE
    10/20/2025$165.00Overweight → Equal Weight
    Barclays
    KLA Corporation
    $KLAC
    10/20/2025$1200.00Equal Weight → Overweight
    Barclays
    HP Inc.
    $HPQ
    10/14/2025$30.00Hold → Buy
    HSBC Securities
    Intel Corporation
    $INTC
    10/13/2025$34.00Neutral → Underperform
    BofA Securities
    Intel Corporation
    $INTC
    10/8/2025$24.00Hold → Reduce
    HSBC Securities
    Intel Corporation
    $INTC
    9/25/2025Sell → Neutral
    Seaport Research Partners
    Intel Corporation
    $INTC
    9/22/2025Sell → Hold
    Erste Group
    KLA Corporation
    $KLAC
    9/22/2025$1093.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lumentum downgraded by Barclays with a new price target

    Barclays downgraded Lumentum from Overweight to Equal Weight and set a new price target of $165.00

    10/20/25 8:37:21 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    KLA Corporation upgraded by Barclays with a new price target

    Barclays upgraded KLA Corporation from Equal Weight to Overweight and set a new price target of $1,200.00

    10/20/25 8:24:18 AM ET
    $KLAC
    Electronic Components
    Technology

    HP Inc. upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded HP Inc. from Hold to Buy and set a new price target of $30.00

    10/14/25 8:37:36 AM ET
    $HPQ
    Computer Manufacturing
    Technology

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

             EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (NASDAQ:EDAP) ("EDAP" or the "Company"), a global leader in robotic, energy-based therapeutic technologies, today announced that it has entered into a €36 million multi-tranche credit facility (the "Credit Facility") with the European Investment Bank (the "EIB"). Proceeds from the financing will be used to support the continued global expansion of the Company's Focal One Robotic High-Intensity Focused Ultrasound (HIFU) platform. The funds will also accelerate the development of new clinical indications for the Compan

    10/20/25 8:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $ARAY
    $EDAP
    $HPQ
    $INTC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Accuray Incorporated

    DEFA14A - ACCURAY INC (0001138723) (Filer)

    10/20/25 5:10:11 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by EDAP TMS S.A.

    6-K - EDAP TMS SA (0001041934) (Filer)

    10/20/25 9:25:20 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Accuray Incorporated

    8-K - ACCURAY INC (0001138723) (Filer)

    10/20/25 9:20:06 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Whitters Joseph E bought $62,335 worth of shares (50,000 units at $1.25), increasing direct ownership by 9% to 611,053 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    6/16/25 4:10:10 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    CEO Gelsinger Patrick P bought $251,198 worth of shares (11,150 units at $22.53), increasing direct ownership by 12% to 105,033 units (SEC Form 4)

    4 - INTEL CORP (0000050863) (Issuer)

    11/6/24 4:06:28 PM ET
    $INTC
    Semiconductors
    Technology

    CEO Gelsinger Patrick P bought $251,946 worth of shares (12,500 units at $20.16) (SEC Form 4)

    4 - INTEL CORP (0000050863) (Issuer)

    8/7/24 4:23:22 PM ET
    $INTC
    Semiconductors
    Technology

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer and GC Jacobs Julie M converted options into 128,944 shares and covered exercise/tax liability with 52,661 shares, increasing direct ownership by 50% to 230,084 units (SEC Form 4)

    4 - HP INC (0000047217) (Issuer)

    10/7/25 4:18:16 PM ET
    $HPQ
    Computer Manufacturing
    Technology

    President and CEO Lores Enrique sold $920,472 worth of shares (34,282 units at $26.85), decreasing direct ownership by 100% to 3 units (SEC Form 4)

    4 - HP INC (0000047217) (Issuer)

    10/1/25 4:54:18 PM ET
    $HPQ
    Computer Manufacturing
    Technology

    President, Semi. Prod. & Cust. Khan Ahmad A. sold $4,107,600 worth of shares (4,564 units at $900.00), decreasing direct ownership by 17% to 22,808 units (SEC Form 4)

    4 - KLA CORP (0000319201) (Issuer)

    9/9/25 4:05:05 PM ET
    $KLAC
    Electronic Components
    Technology

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Pitney Bowes Appoints Accomplished Shipping and Technology Leader Todd Everett as President of Sending Technology Solutions

    Also Appoints Experienced Public Company Director Wayne Walker as Independent Member of the Board Announces Actions to Help Realize the Full Value of The Pitney Bowes Bank and the Company's Global Financial Services Business Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or, the "Company"), a technology-driven products and services company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the following actions associated with the initial phase of its strategic review announced in May 2025: The Appointment of Todd Everett as EVP and President of Sending Technology Solutions ("SendTech"): Mr. Everett has approxi

    9/12/25 8:10:00 AM ET
    $INTC
    $PBI
    $POWW
    Semiconductors
    Technology
    Office Equipment/Supplies/Services
    Miscellaneous

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Financials

    Live finance-specific insights

    View All

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    Mobileye Announces Timing of its Third Quarter 2025 Results

    Mobileye Global Inc. (NASDAQ:MBLY) ("Mobileye") today announced that it will release its financial results for the third quarter 2025 on Thursday, October 23rd, 2025, before market open. Mobileye will host a conference call at 8:00am ET (3:00pm IT) to review its results and provide a general business update. The call will be hosted by Professor Amnon Shashua, CEO, Moran Shemesh Rojansky, CFO, Nimrod Nehushtan, EVP – Business Development and Strategy, and Dan Galves, CCO. The conference call will be accessible live via a webcast on Mobileye's investor relations site, which can be found at https://ir.mobileye.com, and a replay of the webcast will be made available shortly after the event's

    10/9/25 7:00:00 AM ET
    $INTC
    $MBLY
    Semiconductors
    Technology
    Computer Software: Prepackaged Software

    Intel to Report Third-Quarter 2025 Financial Results

    Intel Corporation today announced that it will report third-quarter financial results on Thursday, October 23, 2025, promptly after close of market. Intel will then hold an earnings conference call at 2 p.m. PDT that day to discuss the results. A live public webcast of the earnings conference call can be accessed on Intel's Investor Relations website at intc.com. Associated materials and webcast replay will also be available on the site. About Intel Intel (NASDAQ:INTC) designs and manufactures advanced semiconductors that connect and power the modern world. Every day, our engineers create new technologies that enhance and shape the future of computing to enable new possibilities for e

    10/8/25 4:30:00 PM ET
    $INTC
    Semiconductors
    Technology

    $ARAY
    $EDAP
    $HPQ
    $INTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lumentum Holdings Inc.

    SC 13G/A - Lumentum Holdings Inc. (0001633978) (Subject)

    11/14/24 7:53:37 PM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    11/14/24 3:36:33 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by HP Inc.

    SC 13G/A - HP INC (0000047217) (Subject)

    11/12/24 3:53:24 PM ET
    $HPQ
    Computer Manufacturing
    Technology